SCHEDULE 13G/A: Nantahala Capital Management Discloses 9.99% Stake in TELA Bio, Inc.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 9.99% of TELA Bio, Inc.'s common stock as of December 31, 2024.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have reported beneficial ownership of 3,974,326 shares of TELA Bio, Inc. common stock.
• This aggregate amount represents 9.99% of the total outstanding common stock of TELA Bio, Inc.
• The reported shares include 394,600 shares that the Reporting Persons may acquire within sixty days through the exercise of warrants.
• The shares are held by funds and separately managed accounts under the control of Nantahala Capital Management, LLC.
• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, is identified as having the right to receive dividends or proceeds from the sale of more than five percent of the outstanding shares beneficially owned by Nantahala.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of TELA Bio, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain qualitative statements about the company's performance or outlook, thus a neutral sentiment score is appropriate.

Positives

• The disclosure of a significant 9.99% stake by an institutional investor like Nantahala Capital Management could be interpreted as a vote of confidence in TELA Bio, Inc.'s long-term prospects.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding TELA Bio, Inc.'s future performance or operations.

Industry Context

This filing is a standard disclosure of a significant ownership stake by an investment firm in a publicly traded company within the healthcare or medical device sector (TELA Bio, Inc. is a medical technology company). Such disclosures are common and reflect investment decisions by institutional players.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may be viewed positively, potentially signaling confidence in the company's value or future prospects.

Key Dates

Keywords

TELA Bio Inc., Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Wilmot B. Harkey, Daniel Mack, Warrants